Exhibitors
Roche Diagnostics
As a global leader in healthcare, Roche Diagnostics offers a broad portfolio of tools that help healthcare providers in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as other medical conditions, such as fertility and blood coagulation. These products and services are used by researchers, physicians, patients, hospitals and laboratories worldwide to help improve people’s lives.
Scientifically formulated by Carol Locke, M.D., while on faculty at Harvard Medical School, OmegaBrite is a pharmaceutical-quality, concentrated high EPA Omega-3 fatty acid supplement from fish oil promoting positive mood, cardiac and joint health, and overall well being. Located in Waltham, Massachusetts, the company uses the most advanced manufacturing processes to provide the highest purity Omega-3 products on the market.
The American Heart Association recommends the importance of the Omega-3 essential nutrients EPA and DHA in promoting cardiac health, lowering blood triglycerides and in protecting against cardiovascular disease. The high EPA Omega-3 in OmegaBrite provides important anti-inflammatory protection for heart and overall health. The American Heart Association recommends that all individuals with a history of cardiac disease take up to 2 grams of Omega-3 EPA and Omega-3 DHA each day. In addition new research published in the JELIS study shows that even in those individuals eating a high fish diet and on statins, taking a high EPA Omega-3 supplement further improves cardiac health. For those individuals who are on a statin therapy, a study published in the American Journal of Cardiology in August 2006 recommends that all individuals on a statin also benefit from taking an Omega-3.
More information can be found at www.omegabrite.com.
FirstLine Therapy® by Metagenics
The Need: Your patients need your help to change their unhealthy lifestyle habits. Unhealthy lifestyles are recognized as a primary underlying cause of cardiovascular disease, diabetes, hypertension, dyslipidemia and many other chronic health problems. Leading health organizations are now encouraging physicians to make therapeutic lifestyle changes (TLC) a meaningful part of patient care.
The Problem: Most physicians find that time constraints, financial pressures, or lack of appropriate tools and training make it difficult to address lifestyle issues in everyday clinical practice.
The Solution: FirstLine Therapy (FLT) by Metagenics’ is an evidence based, clinically effective, turn-key TLC program. FirstLine Therapy allows you to address your patients lifestyle habits in a practical and clinically meaningful way, as you increase revenue and enhance the profitability of your practice. For more information, visit www.metagenics.com/tlc.
NMT's industry-firsts in noninvasive hemodynamic and fluid status monitors assist clinicians in managing people with chronic conditions like CHF, CAD, HTN, and ESRD. Mission: "To save lives by continually advancing the standard for noninvasive patient monitoring across the care continuum, while maximizing clinical, medical, and financial outcomes, and promoting scientific innovation." We receive industry acclaim and validation of technological advancements in remote patient monitoring.
McGraw-Hill’s AccessMedicine is an innovative online product that provides students, residents, clinicians, professors, researchers and all health professionals with more than 50 leading medical books, including Hurst’s the Heart, Harrison’s Online, and CMDT. AccessMedicine also offers updated articles and reviews, hundreds of illustrations, a self-assessment feature, videos, animations, and audio files, case files, a comprehensive search platform, and the ability to download content to a mobile device. McGraw-Hill Professional is a leading global provider of electronic and print content and services for scientific, technical, and medical communities. Its online medical offerings include products in general and evidence-based medicine, pharmacy, emergency medicine, genetics, internal medicine, surgery, anesthesiology, and test preparation. More information can be found at www.accessmedicine.com and www.mcgraw-hillmedical.com.
Philips Healthcare a diversified health and well-being company, focused on improving people’s lives through timely innovations. Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity." Now you can have high quality imaging healthcare solutions throughout life using the Philips family of echocardiography systems with advanced 2D and 3D imaging and quantification tools. Please visit www.philips.com/healthcare for more information on Philips Healthcare and to see our full suite of cardiology ultrasound solutions.
.bmp){kind=small}
As one of the world’s leading pharmaceutical companies, our business is focused on turning -Discovering, developing, and delivering innovative, meaningful medicines and other -Putting the health of patients first by providing educational programs, resources, and -Creating a challenging and rewarding work environment that inspires our employees
CRESTOR® (rosuvastatin calcium) —the fastest growing branded statin among cardiologists
In November 2007, CRESTOR was also approved to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total-C and LDL-C to target levels.4
With proven efficacy in reducing LDL-C, increasing HDL-C, and slowing the progression of
CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).4,5
Please click here for Important Safety Information for CRESTOR.
Please click here for full Prescribing Information for CRESTOR.
* Based on NRx share growth with cardiologists and internists, relative to other branded statins in the market, during the time period
References: 1. Data on File, 272072, AstraZeneca Pharmaceuticals LP. 2. Data on File, 272073, AstraZeneca Pharmaceuticals LP.
CRESTOR is a registered trademark of the AstraZeneca group of companies.
